MCID: RNL011
MIFTS: 50

Renal Osteodystrophy

Categories: Bone diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Osteodystrophy

MalaCards integrated aliases for Renal Osteodystrophy:

Name: Renal Osteodystrophy 12 74 54 15 17 71 32
Renal Rickets 12 74 52 71
Chronic Kidney Disease-Mineral and Bone Disorder 43

Classifications:



External Ids:

Disease Ontology 12 DOID:13068
ICD9CM 34 588.0
MeSH 43 D012080
NCIt 49 C114827
SNOMED-CT 67 16726004
ICD10 32 N25.0
UMLS 71 C0035086 C1527410

Summaries for Renal Osteodystrophy

MalaCards based summary : Renal Osteodystrophy, also known as renal rickets, is related to osteitis fibrosa and bone inflammation disease. An important gene associated with Renal Osteodystrophy is PTH (Parathyroid Hormone), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and G alpha (s) signalling events. The drugs Sevelamer and Parathyroid hormone have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and testes, and related phenotypes are growth/size/body region and endocrine/exocrine gland

Wikipedia : 74 Renal osteodystrophy is currently defined as an alteration of bone morphology in patients with chronic... more...

Related Diseases for Renal Osteodystrophy

Diseases related to Renal Osteodystrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 249)
# Related Disease Score Top Affiliating Genes
1 osteitis fibrosa 32.3 PTH FGF23 CASR CALCA BGLAP
2 bone inflammation disease 31.1 TNFSF11 TNFRSF11B ACP5
3 end stage renal failure 30.8 PTH EPO CALCA BGLAP
4 rickets 30.6 VDR PTH FGF23 CASR BGLAP
5 fibrous dysplasia 30.6 FGF23 CALCA BGLAP
6 spondyloarthropathy 30.5 TNFSF11 SLPI CALCA
7 metabolic acidosis 30.5 PTH FGF23 BGLAP
8 osteomalacia 30.5 VDR TNFSF11 PTH FGF23 CASR CALCA
9 hyperphosphatemia 30.4 VDR TNFRSF11B PTH FGF23 CASR BGLAP
10 calcinosis 30.4 PTH FGF23 CALCA
11 hyperostosis 30.2 TNFRSF11B SOST FGF23
12 uremia 30.2 VDR TNFRSF11B PTH EPO CASR
13 endosteal hyperostosis, autosomal dominant 30.0 TNFSF11 TNFRSF11B SOST PTH ACP5
14 graves disease 1 30.0 PTH CALCA
15 osteomyelitis 29.9 TNFSF11 CALCA ACP5
16 nephrocalcinosis 29.8 PTH FGF23 CASR
17 spondyloarthropathy 1 29.8 TNFSF11 TNFRSF11B PTH BGLAP
18 osteonecrosis 29.8 TNFSF11 TNFRSF11B PTH BGLAP ACP5
19 periapical periodontitis 29.8 TNFSF11 TNFRSF11B ACP5
20 synovitis 29.8 TNFSF11 TNFRSF11B ACP5
21 kidney disease 29.7 VDR TNFRSF11B SLPI PTH FGF23 EPO
22 hyperthyroidism 29.5 PTH CALCA BGLAP ACP5
23 myelofibrosis 29.5 TNFRSF11B PTH EPO ACP5
24 mammary paget's disease 29.3 TNFSF11 TNFRSF11B PTH CALCA BGLAP ACP5
25 hypophosphatemia 29.3 VDR PTH1R PTH FGF23 BGLAP
26 periodontitis 29.3 VDR TNFSF11 TNFRSF11B BGLAP ACP5
27 hypocalcemia, autosomal dominant 1 29.3 VDR PTH FGF23 CASR CALCA BGLAP
28 pseudohypoparathyroidism 29.2 PTH1R PTH CALCA BGLAP
29 calciphylaxis 29.2 VDR PTH FGF23 EPO CASR
30 osteopetrosis 29.2 TNFSF11 TNFRSF11B CALCA BGLAP ACP5
31 sclerosteosis 29.1 VDR TNFSF11 TNFRSF11B SOST PTH BGLAP
32 secondary hyperparathyroidism 28.9 VDR TNFRSF11B SLPI PTH FGF23 EPO
33 hypercalcemia, infantile, 1 28.9 VDR PTH1R PTH CASR CALCA
34 otosclerosis 28.8 VDR TNFSF11 TNFRSF11B PTH1R CALCA
35 hypoparathyroidism 28.8 VDR PTH1R PTH FGF23 CASR CALCA
36 hyperparathyroidism 28.2 VDR TNFSF11 TNFRSF11B SOST SLPI PTH
37 paget's disease of bone 28.2 VDR TNFSF11 TNFRSF11B SOST PTH CASR
38 glucocorticoid-induced osteoporosis 28.1 VDR TNFSF11 TNFRSF11B SOST PTH CALCA
39 bone resorption disease 27.8 VDR TNFSF11 TNFRSF11B SOST PTH1R PTH
40 chronic kidney disease 27.6 VDR TNFSF11 TNFRSF11B SOST SLPI PTH
41 brittle bone disorder 27.4 TNFSF11 TNFRSF11B SOST PTH1R PTH CALCA
42 bone disease 27.3 VDR TNFSF11 TNFRSF11B SOST SLPI PTH1R
43 primary hyperparathyroidism 27.2 VDR TNFSF11 TNFRSF11B SOST PTH1R PTH
44 osteoporosis 25.4 VDR TNFSF11 TNFRSF11B SOST SLPI PTH1R
45 arterial calcification, generalized, of infancy, 1 10.4
46 hypocalciuric hypercalcemia, familial, type i 10.4 PTH CASR
47 hypocalciuric hypercalcemia, familial, type ii 10.4 PTH CASR
48 hypocalciuric hypercalcemia, familial, type iii 10.4 PTH CASR
49 polyarticular onset juvenile idiopathic arthritis 10.4 TNFSF11 TNFRSF11B
50 hypercalciuria, absorptive, 2 10.4 VDR CASR

Comorbidity relations with Renal Osteodystrophy via Phenotypic Disease Network (PDN):


Acute Cystitis Acute Kidney Failure
Deficiency Anemia Heart Disease
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Renal Osteodystrophy:



Diseases related to Renal Osteodystrophy

Symptoms & Phenotypes for Renal Osteodystrophy

MGI Mouse Phenotypes related to Renal Osteodystrophy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.02 CASR FGF23 IGFBP4 IGFBP5 PTH PTH1R
2 endocrine/exocrine gland MP:0005379 9.97 CASR FGF23 IGFBP4 IGFBP5 PTH PTH1R
3 hematopoietic system MP:0005397 9.91 CASR EPO FGF23 PTH PTH1R SLPI
4 immune system MP:0005387 9.85 CASR EPO FGF23 IGFBP1 PTH PTH1R
5 limbs/digits/tail MP:0005371 9.56 EPO FGF23 PTH PTH1R SOST TNFRSF11B
6 skeleton MP:0005390 9.28 CASR EPO FGF23 PTH PTH1R SOST

Drugs & Therapeutics for Renal Osteodystrophy

Drugs for Renal Osteodystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 4 52757-95-6
2
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
3
Zoledronic Acid Approved Phase 4 118072-93-8 68740
4
tannic acid Approved Phase 4 1401-55-4
5
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
6
Pamidronate Approved Phase 4 40391-99-9 4674
7
Phylloquinone Approved, Investigational Phase 4 84-80-0
8
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
9
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
10 Menaquinone Investigational Phase 4 1182-68-9
11 1 alpha-hydroxyergocalciferol Phase 4
12 Vasoconstrictor Agents Phase 4
13 Antifibrinolytic Agents Phase 4
14 Coagulants Phase 4
15 naphthoquinone Phase 4
16 Hemostatics Phase 4
17 Vitamin K 2 Phase 4
18 Vitamin MK 7 Phase 4
19 Vitamin K Phase 4
20
Calcium carbonate Approved, Investigational Phase 3 471-34-1
21
Calcium acetate Approved, Investigational Phase 3 62-54-4
22
carbamide peroxide Approved Phase 3 124-43-6
23
Alendronate Approved Phase 2, Phase 3 66376-36-1, 121268-17-5 2088
24
Denosumab Approved Phase 2, Phase 3 615258-40-7
25
Calcifediol Approved, Nutraceutical Phase 3 19356-17-3 5283731 6433735
26
Calcitriol Approved, Nutraceutical Phase 2, Phase 3 32222-06-3 134070 5280453
27 Chelating Agents Phase 3
28 Hormone Antagonists Phase 3
29 Hormones Phase 3
30 Diphosphonates Phase 2, Phase 3
31 Antibodies, Monoclonal Phase 2, Phase 3
32 Antibodies Phase 2, Phase 3
33 Immunoglobulins Phase 2, Phase 3
34
Nicotinamide Approved, Investigational Phase 1, Phase 2 98-92-0 936
35
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
36
Niacin Approved, Investigational, Nutraceutical Phase 1, Phase 2 59-67-6 938
37 Anti-Ulcer Agents Phase 2
38 Gastrointestinal Agents Phase 2
39 Dihydroxycholecalciferols Phase 2
40 Phytosterol Phase 2
41 Antacids Phase 2
42 Pharmaceutical Solutions Phase 2
43 Dialysis Solutions Phase 2
44 Hypolipidemic Agents Phase 1, Phase 2
45 Vitamin B Complex Phase 1, Phase 2
46 Vitamin B3 Phase 1, Phase 2
47 Vitamin B9 Phase 1, Phase 2
48 Folate Phase 1, Phase 2
49 Vasodilator Agents Phase 1, Phase 2
50 Antimetabolites Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Regulation of Bone Mineralization in Renal Osteodystrophy Unknown status NCT01799317 Phase 4 Vitamin D2
2 A Prospective and Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year After Kidney Transplantation Completed NCT01675089 Phase 4 Zoledronic acid
3 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
4 The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients Completed NCT02056730 Phase 4 calcium sensing receptor agonist
5 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
6 Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved? Completed NCT02876354 Phase 4 Menaquinone
7 Effect of Non-calcium Phosphate Binders Versus Calcium Based Binders on Chronic Kidney Disease -Mineral and Bone Disorder in Children on Regular Hemodialysis Unknown status NCT03202407 Phase 3 Calcium acetate and sevelamer hydrochloride
8 VITA-D: Cholecalciferol Substitution in Vitamin D Deficient Kidney Transplant Recipients: A Randomized, Placebo-controlled Study to Evaluate the Posttransplant Outcome Unknown status NCT00752401 Phase 3 Cholecalciferol;Placebo
9 TIW Growth Hormone Therapy in Children on Hemodialysis Completed NCT00943995 Phase 3 somatropin
10 Evaluation of the Efficacy and Tolerability of Alendronate Versus Denosumab in Kidney Transplant Patients With Reduced Bone Mineral Density Recruiting NCT04169698 Phase 2, Phase 3 Denosumab 60 mg/ml [Prolia];Alendronate 70Mg Tab
11 Effect of Non-Surgical Periodontal Therapy on Serum Albumin Levels of Patients on Maintenance Hemodialysis Therapy, A Randomized Control Trial Unknown status NCT01641757 Phase 2
12 A Multicenter, Randomized, Placebo-controlled, Double-blind, 12-month Study to Assess the Effects of an Oral Calcimimetic Agent (AMG 073) on Renal Osteodystrophy in Hemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00527085 Phase 2 AMG 073;Placebo
13 Regulation of Bone Formation in Renal Osteodystrophy Completed NCT00560300 Phase 2 1 alpha D2;1,25 dihydroxy vitamin D3;Sevelamer HCl;Calcium Carbonate
14 Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis Completed NCT00004340 Phase 2 calcitriol;growth hormone
15 A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder Completed NCT01414114 Phase 2 Etelcalcetide
16 The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects With End-Stage Renal Disease Treated With Haemodialysis - A Randomised Clinical Trial Completed NCT02977117 Phase 2
17 The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients Completed NCT00508885 Phase 1, Phase 2 Niacinamide;Placebo
18 An Evaluation of Chewed vs. Crushed Lanthanum Carbonate in the Efficacy of Phosphate Binding in Hemodialysis Patients Completed NCT00660530 Phase 2 Lanthanum carbonate;Lanthanum carbonate
19 Isoflavones and Acute-phase Response in Chronic Renal Failure Completed NCT00029796 Phase 2 soy isoflavones
20 Multicentered, Randomized Study of Safety and Efficacy of Whole-body Vibration as add-on to Standard Pharmacological Treatment of Osteoporosis in Post-menopausal Women Completed NCT01415050 Phase 2
21 The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease Recruiting NCT03960437 Phase 2 Etelcalcetide
22 The Effects of 12-months of Denosumab on Bone Density, Quality and Strength in Prevalent Kidney Transplant Recipients Recruiting NCT03960554 Phase 2 Denosumab Inj 60 mg/ml
23 A Multicenter Open-label Extension Study to Assess the Long-term Safety and Efficacy of KAI-4169 (Also Known as AMG 416) in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Patients With Secondary Hyperparathyroidism Terminated NCT01576146 Phase 2 Etelcalcetide
24 Effect of Kidney Yin/Yang Replenishment on Bone Metabolism in Patients With Renal Osteodystrophy Withdrawn NCT01665651 Phase 2 Yougui granules;Zuogui granules;Yougui granules placebo;Zuogui granules placebo
25 Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate Completed NCT00458289 Phase 1 Lanthanum carbonate (chewed vs. crushed)
26 The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients Completed NCT00316472 Phase 1 Niacinamide
27 The Association of Serum Sclerostin Levels,Echocardiographic Parameters, Arteriovenous Fistula Thrombosis and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients Unknown status NCT01382966
28 Investigation to Develop Standard Operating Procedures (SOP) for the Determination of Innovative CKD-MBD(Chronic Kidney Disease - Mineral Bone Disorder)-Serum-(Plasma-)Parameters Unknown status NCT02708368
29 A Prospective Observational Study to Investigate the Natural History of Bone Histomorphometry and Vascular Calcification in Dialysis-dependent Patients Before and After Renal Transplantation. Unknown status NCT01886950
30 Molecular and Cellular Mechanism of Vascular Ageing in Chronic Kidney Disease: Role of Theranova Dialyzer on Mineral Metabolism Disorder, Oxidative Stress, and Vascular Calcification Unknown status NCT03169400
31 Renal Osteodystrophy: A Fresh Approach Completed NCT00859612
32 Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in CKD Completed NCT00285467 doxercalciferol;Cholecalciferol
33 Low Magnitute Mechanical Stimuli Effects on Bone Structure in ESRD Completed NCT00364234
34 Clinical Outcomes and Costs of 4-Week Versus 6-Week Bloodwork for Patients on Hemodialysis Completed NCT03659500
35 Intact Versus Biointact Assays for Longitudinal Assessment of Parathyroid Hormone - The Longitudinal PTH Study Completed NCT03464149
36 Artificial Intelligence: to Analyse CKD-MBD in Hemodialysis and Cardiovascular Risk Completed NCT02697578
37 A Correlation Between Histological Findings of the Blood Vessels in Patients With Chronic Renal Failure and Serum Uremic Toxins and Its Diagnostic Performance in the Assessment of the Cardiovascular Morbidity and Mortality Completed NCT00412139
38 Phosphate Intake's Effect on the Skeletal System Calcitropic Hormones and FGF23 - Pilot Study Completed NCT00187629
39 Intensive Patient Education Using the Phosphorus Point System© Tool to Improve Serum Phosphorus Levels in Patients With Chronic Kidney Disease Completed NCT00656279
40 Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation - A Monocentric Study Completed NCT02523209
41 Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease Completed NCT00781417
42 A Pilot Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation Completed NCT00124410
43 Effect of Probiotics on Modulating the Bacterial Translocation and Improving Micro-inflammation in Hemodialysis Patients Completed NCT02929225 Early Phase 1 Bifid Triple Viable Capsules
44 Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function Can 18F-PET Replace Bone Histomorphometry Recruiting NCT03716128
45 Continuous Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency in Different Stages Recruiting NCT02147782
46 Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Recruiting NCT02556216
47 Assessing Calcium Balance in Children With Chronic Kidney Disease to Optimise Treatment Strategies Recruiting NCT03285854
48 Renal Osteodystrophy: A Fresh Approach Recruiting NCT02440581 Alendronate;Teriparatide;Cinacalcet
49 Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients: a Prospective Cohort Study Recruiting NCT03937349
50 Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease Recruiting NCT03626246

Search NIH Clinical Center for Renal Osteodystrophy

Cochrane evidence based reviews: chronic kidney disease-mineral and bone disorder

Genetic Tests for Renal Osteodystrophy

Anatomical Context for Renal Osteodystrophy

MalaCards organs/tissues related to Renal Osteodystrophy:

40
Bone, Kidney, Testes, Liver, Bone Marrow, Prostate, Cortex

Publications for Renal Osteodystrophy

Articles related to Renal Osteodystrophy:

(show top 50) (show all 2263)
# Title Authors PMID Year
1
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. 54 61
19050056 2009
2
PHEX, FGF23, DMP1 and beyond. 54 61
18660670 2008
3
Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. 54 61
16117195 2005
4
Parathyroid hormone decreases renal vitamin D receptor expression in vivo. 54 61
15769857 2005
5
Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients. 54 61
16686316 2005
6
Osteoprotegerin and bone mineral density in hemodiafiltration patients. 54 61
16152990 2005
7
Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients. 61 54
15665550 2005
8
Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. 54 61
15199292 2004
9
Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. 61 54
15631342 2004
10
Correlations of new markers of bone formation and resorption in kidney transplant recipients. 54 61
12826157 2003
11
Musculoskeletal manifestations of chronic renal failure. 61 54
12496510 2003
12
Pathogenesis and treatment of renal osteodystrophy. 54 61
12944733 2003
13
Increased levels of osteoprotegerin in hemodialysis patients. 61 54
12476941 2002
14
Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. 61 54
11877577 2002
15
Calcitonin as a helper of calcitriol therapy in renal osteodystrophy. 54 61
11096303 2000
16
Calcium supplement necessary to correct hypocalcemia after total parathyroidectomy for renal osteodystrophy. 61 54
10710245 2000
17
Evaluation of IGF system component levels and mitogenic activity of uremic serum on normal human osteoblasts. 61 54
10657717 2000
18
Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. 61 54
10652019 2000
19
Serum interleukin-6 in renal osteodystrophy: relationship with serum PTH and bone remodeling markers. 61 54
10077343 1999
20
Characteristics of biochemical markers in patients with metabolic bone disorders. 54 61
9553754 1998
21
Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. 61 54
9127327 1997
22
Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. 54 61
8704118 1996
23
Is calcitonin a helper of phosphate binders in the control of renal osteodystrophy? 54 61
8559512 1995
24
Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. 54 61
7724029 1995
25
Renal osteodystrophy with hyperparathyroidism: the diagnostic value of intact parathormone, alkaline phosphatase, osteocalcin and procollagen. 54 61
7865545 1994
26
Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. 54 61
8258962 1993
27
[Calcitonin for therapy of renal osteodystrophy due to long-term hemodialysis in patients with chronic kidney failure]. 61 54
1808343 1991
28
Endosteal surfaces in hyperparathyroidism: an enzyme cytochemical study on low-temperature-processed, glycol-methacrylate-embedded bone biopsies. 61 54
1750188 1991
29
[Diagnostic evaluation of plasma free gamma-carboxyglutamic acid in maintenance hemodialytic patients with renal osteodystrophy]. 61 54
2082053 1990
30
Measurement of serum bone gla-protein (BGP) in humans with an ovine BGP-based radioimmunoassay. 54 61
2208702 1990
31
Osteocalcin, iPTH, alkaline phosphatase and hand X-ray scores as predictive indices of histomorphometric parameters in renal osteodystrophy. 54 61
2077408 1990
32
Bone mineral density at different sites and 5 years mortality in end-stage renal disease patients: A cohort study. 61
31669253 2020
33
Bisphosphonate therapy in CKD: the current state of affairs. 61
31833938 2019
34
Surgical osteoplasty and soft tissue excision as treatment for facial deformities in patients with renal osteodystrophy: three case reports. 61
31832899 2019
35
Hospitalized fracture rates amongst patients with chronic kidney disease in Australia using data linkage. 61
31743530 2019
36
The association between chronic kidney disease, falls, and fractures: a systematic review and meta-analysis. 61
31720721 2019
37
Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats. 61
31398464 2019
38
Thoracic Deformity and Acro-Osteolysis in Severe Renal Osteodystrophy. 61
31685157 2019
39
Racial differences in bone histomorphometry in children and young adults treated with dialysis. 61
31181383 2019
40
Management of bone disease in cystinosis: Statement from an international conference. 61
31177550 2019
41
Strategies for Phosphate Control in Patients With CKD. 61
31440695 2019
42
C-type natriuretic peptide attenuates renal osteodystrophy through inhibition of FGF-23/MAPK signaling. 61
31263178 2019
43
[Osteoporosis and chronic kidney disease: review and new therapeutic strategies]. 61
31373465 2019
44
Teriparatide Treatment for Hypercalcemia Associated With Adynamic Bone Disease. 61
31372586 2019
45
Renal insufficiency and bone loss. 61
31135568 2019
46
Comparison of skeletal changes related to patients with chronic kidney disease and healthy individuals in digital panoramic radiography. 61
31397408 2019
47
Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. 61
30797619 2019
48
Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
. 61
30862350 2019
49
The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats. 61
30801205 2019
50
A Unique Association of Osteogenesis Imperfecta with Bilateral Renal Osteodystrophy and Gastroenteritis in a Three-year-old Boy. 61
31249745 2019

Variations for Renal Osteodystrophy

Expression for Renal Osteodystrophy

Search GEO for disease gene expression data for Renal Osteodystrophy.

GO Terms for Renal Osteodystrophy

Cellular components related to Renal Osteodystrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.73 VDR PTH1R PTH FGF23 CASR CALCA
2 extracellular region GO:0005576 9.73 TNFSF11 TNFRSF11B SOST SLPI PTH IGFBP5
3 endoplasmic reticulum lumen GO:0005788 9.55 IGFBP5 IGFBP4 IGFBP1 FGF23 BGLAP
4 extracellular space GO:0005615 9.4 TNFSF11 TNFRSF11B SOST SLPI PTH IGFBP5

Biological processes related to Renal Osteodystrophy according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.13 VDR TNFRSF11B PTH1R IGFBP5 IGFBP4 IGFBP1
2 post-translational protein modification GO:0043687 9.92 IGFBP5 IGFBP4 IGFBP1 FGF23
3 cellular protein metabolic process GO:0044267 9.8 IGFBP5 IGFBP4 IGFBP1 FGF23 CALCA
4 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.79 PTH1R PTH CALCA
5 cellular calcium ion homeostasis GO:0006874 9.73 VDR PTH1R PTH CASR
6 skeletal system development GO:0001501 9.72 VDR TNFRSF11B PTH1R PTH BGLAP
7 response to estrogen GO:0043627 9.69 TNFRSF11B EPO BGLAP
8 regulation of bone mineralization GO:0030500 9.64 FGF23 BGLAP
9 negative regulation of ossification GO:0030279 9.64 SOST CALCA
10 osteoblast development GO:0002076 9.63 PTH1R BGLAP
11 response to vitamin D GO:0033280 9.63 PTH BGLAP
12 regulation of osteoclast differentiation GO:0045670 9.62 TNFSF11 BGLAP
13 negative regulation of bone resorption GO:0045779 9.61 TNFRSF11B CALCA
14 response to inorganic substance GO:0010035 9.6 TNFRSF11B BGLAP
15 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.59 IGFBP5 IGFBP4
16 vitamin D metabolic process GO:0042359 9.58 VDR FGF23
17 response to magnesium ion GO:0032026 9.58 TNFRSF11B FGF23
18 type B pancreatic cell proliferation GO:0044342 9.57 IGFBP5 IGFBP4
19 cellular response to parathyroid hormone stimulus GO:0071374 9.56 SOST FGF23
20 response to fibroblast growth factor GO:0071774 9.55 PTH CASR
21 positive regulation of inositol phosphate biosynthetic process GO:0060732 9.54 PTH1R PTH
22 cellular response to vitamin D GO:0071305 9.54 FGF23 CASR BGLAP
23 phosphate ion homeostasis GO:0055062 9.49 PTH FGF23
24 negative regulation of calcium ion transport into cytosol GO:0010523 9.48 EPO CALCA
25 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.46 VDR FGF23
26 bone resorption GO:0045453 9.46 TNFSF11 PTH1R PTH ACP5
27 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.43 IGFBP5 IGFBP4 IGFBP1
28 aging GO:0007568 9.43 PTH1R IGFBP5 IGFBP1 EPO CALCA BGLAP
29 ossification GO:0001503 9.1 TNFSF11 SOST PTH1R CASR BGLAP ACP5

Molecular functions related to Renal Osteodystrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 PTH EPO CALCA
2 growth factor binding GO:0019838 9.43 IGFBP5 IGFBP4 IGFBP1
3 insulin-like growth factor binding GO:0005520 9.33 IGFBP5 IGFBP4 IGFBP1
4 insulin-like growth factor I binding GO:0031994 9.13 IGFBP5 IGFBP4 IGFBP1
5 insulin-like growth factor II binding GO:0031995 8.8 IGFBP5 IGFBP4 IGFBP1

Sources for Renal Osteodystrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....